NCT07319286Enrolling by invitationPhase 1/2
Role of Glucagon-like Peptide-1 Receptor Agonists in Menstrual Irregularities in Adolescent Females With Type 1 Diabetes Mellitus
Source: ClinicalTrials.gov · Last updated 5 Jun 2026
Brief summary (registry, in English)
The aim of this study is to measure the frequency of menstrual irregularities among adolescent females with Type 1 diabetes mellitus and to assess the therapeutic effect of glucagon-like peptide-1 receptor agonist on menstrual irregularities in adolescent females with Type 1 diabetes mellitus .
- Status (registry)
- Enrolling by invitation
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 5 Dec 2025
- Start date
- 4 Aug 2025
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Ain Shams University
- Diseases
- Type 1 diabetes
- NCT number
- NCT07319286
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 50
- From 4 Aug 2025 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Presence of medical conditions known to cause menstrual irregularities, including:(Connective tissue disorders, Autoimmune diseases, Clinical thyroid dysfunction, Neurological diseases).
- History of severe hypoglycemia within the past 12 months
- Other causes of abnormal uterine bleeding, including:(Structural causes (e.g., leiomyoma, endometrial polyp), Coagulation disorders, Ovulatory disorders (e.g., hyperprolactinemia, hyperandrogenism), Iatrogenic causes (e.g., steroid therapy, oral contraceptive use)
- Family history of medullary thyroid carcinoma or multiple endocrine neoplasia History of pancreatitis
Who the study is looking for
- Diagnosis of Type 1 Diabetes Mellitus according to ISPAD criteria
- Use of continuous glucose monitoring (CGM)
- Receiving regular insulin therapy
- Regular follow-up at a diabetes clinic
- Female participants aged 12 to 18 years
- At least 2 years post-menarche
- Poor glycemic control, defined as HbA1c ≥ 7%
Age in the registry: 12 years to 18 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ain Shams University Coordinator of this site? Confirm its status | Cairo | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.